ORTX - Orchard Therapeutics GAAP EPS of -$0.35 misses by $0.10 revenue of $5.52M beats by $1.48M
Orchard Therapeutics press release (NASDAQ:ORTX): Q1 GAAP EPS of -$0.35 misses by $0.10. Revenue of $5.52M beats by $1.48M. The company expects that its existing cash, cash equivalents and investments of $199M will fund its anticipated operating, debt service and capital expenditure requirements into 2024.
For further details see:
Orchard Therapeutics GAAP EPS of -$0.35 misses by $0.10, revenue of $5.52M beats by $1.48M